Akebia Therapeutics
AKBA
126 hedge funds and large institutions have $282M invested in Akebia Therapeutics in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 49 increasing their positions, 36 reducing their positions, and 22 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 36
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 139 → 126 (-13)
9.88% less ownership
Funds ownership: 66.31% → 56.43% (-9.9%)
16% less call options, than puts
Call options by funds: $1.52M | Put options by funds: $1.8M
29% less capital invested
Capital invested by funds: $399M → $282M (-$118M)
50% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$8.16M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$6.28M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.28M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$3.03M |
| 5 |
BlackRock
New York
|
+$2.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$40.7M |
| 2 |
Goldman Sachs
New York
|
-$7.4M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.74M |
| 4 |
Morgan Stanley
New York
|
-$3.39M |
| 5 |
Renaissance Technologies
New York
|
-$2.51M |
AKBA Hedge Fund Activity: Q3 2021 in Review
126 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2021, worth a combined $282M — down 29% from $399M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AKBA and 11 opened new positions — a net loss of 11 holders — while 36 trimmed existing stakes and 49 added.
The largest buyer was Marshall Wace, adding an estimated $8.16M. The largest seller was Wellington Management Group, exiting entirely with an estimated $40.7M sold.
- 126 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2021, down from 139 in Q2 2021.
- Funds reported $282M of Akebia Therapeutics stock for Q3 2021, down 29% quarter-over-quarter.
- 11 funds opened new Akebia Therapeutics positions in Q3 2021 and 22 closed out, a net change of -11 holders.
- The largest Akebia Therapeutics buyer in Q3 2021 was Marshall Wace, an estimated $8.16M added.
- The largest Akebia Therapeutics seller in Q3 2021 was Wellington Management Group, an estimated $40.7M sold.
Based on aggregated 13F filings for Q3 2021.